Noteworthy, compared to other AML subtypes, AML cells bearing MLL‐ENL + FLT3‐ITD mutations seem to be more prone to reduce syntenin expression in BMSC (Fig 1B; Dataset EV2). The gene discussed is MLLT1; the disease is acute myeloid leukemia.